2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 22:15, 2 December 2023
, 2 December 2023→Clinical Trials
| Line 248: | Line 248: | ||
*The improvement of aerobic capacity is in a dosage-dependent, large dosage of NMN with exercise has better effects. | *The improvement of aerobic capacity is in a dosage-dependent, large dosage of NMN with exercise has better effects. | ||
*The improvement is muscle, not cardiac, related. | *The improvement is muscle, not cardiac, related. | ||
|- | |||
|{{pmid text|34912838}} | |||
*[https://www.nmn.com/news/nmn-improves-telomere-length-blood-cells-middle-aged-people NMN.com article] | |||
|90 days | |||
* 300 mg in warm water | |||
| | |||
* 8 healthy men | |||
* age: 45–60 | |||
|* | |||
* NMN doubles the telomere length of humans over a 90-day period of time. | |||
|- | |- | ||
|{{pmid_text|36002548}} | |{{pmid_text|36002548}} | ||
| Line 261: | Line 274: | ||
*Oral administration of NMN in humans has a low adverse effect on renal function. | *Oral administration of NMN in humans has a low adverse effect on renal function. | ||
*Results indicate that NMN can be administered orally to humans at doses 1250 mg once daily for up to 4 weeks without causing hepatotoxicity and vasodilative flushing, and is believed to have a higher upper tolerable limit compared to NAM and NA. | *Results indicate that NMN can be administered orally to humans at doses 1250 mg once daily for up to 4 weeks without causing hepatotoxicity and vasodilative flushing, and is believed to have a higher upper tolerable limit compared to NAM and NA. | ||
|- | |||
|{{pmid_text|35215405}} | |||
|[[RCT]], 12 weeks | |||
*placebo, before 12 pm | |||
* placebo, after 6 pm | |||
* 250 mg, before 12 pm | |||
* 250 mg, after 6 pm | |||
| | |||
*108 older adults | |||
*≥65 years | |||
| | |||
*NMN intake in the afternoon is more effective in improving lower limb function and reducing drowsiness in older adults. | |||
|- | |||
|{{pmid text|35927255}} | |||
| | |||
| | |||
| | |||
|- | |||
|{{pmid text|35821806}} | |||
|[[RCT]], 60 days | |||
* placebo (n=31) | |||
* 300mg (n=31) | |||
| | |||
* 66 healthy subjects | |||
* age 40-65 | |||
| | |||
* NAD+ levels increase by 11.3% after 30 days, 38% after 60 days | |||
|- | |- | ||
|{{pmid_text|36482258}} | |{{pmid_text|36482258}} | ||
| Line 278: | Line 320: | ||
*significant improvement of six-minute walking test, blood biological age, and SF-36 scores | *significant improvement of six-minute walking test, blood biological age, and SF-36 scores | ||
*900 mg/day oral dose did not give significantly better efficacy than 600 mg/day dose | *900 mg/day oral dose did not give significantly better efficacy than 600 mg/day dose | ||
|- | |- | ||
|{{pmid_text|35182418}} | |{{pmid_text|35182418}} | ||
| Line 322: | Line 351: | ||
*Adverse events similar between groups | *Adverse events similar between groups | ||
*Provides rationale for larger trials on NAD augmentation for cardiometabolic outcomes in older adults | *Provides rationale for larger trials on NAD augmentation for cardiometabolic outcomes in older adults | ||
|- | |- | ||
|{{pmid text|36797393}} | |{{pmid text|36797393}} | ||